OTX-015

OTX-015

Catalog Number:
L002368802APE
Mfr. No.:
APE-A3692
Price:
$276
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          OTX-015 is a potent inhibitor of BRD2, BRD3, and BRD4 with IC50 values range from 92 to 112 nM [1].BRD2, BRD3, and BRD4 belong to BET bromodomain family and play an important role in regulating transcription. BRDs regulate several oncogenes transcription in a variety of cancers and thus have emerged as a promising target [2]. OTX-015 is a selective BRD2, BRD3, and BRD4 inhibitor and inhibits the binding of BRD2, BRD3, and BRD4 to AcH4. Using TR-FRET method and CHO cell lysate harboring BRD2, BRD3, and BRD4 to research the effect of OTX-015, result showed that OTX-015 inhibited BET family binding to AcH4 in a dose-dependent manner and the EC50 values range from 10 to 19 nM. When tested with human tumor cell lines, incubation with OTX-015 for 72 hours inhibited cell proliferation with GI 50 values ranged from 60 to 200 nM [1]. In ALKpos ALCL cell lines, treatment of OTX-015 for 24 h arrested cell proliferation in G1 phase which was more pronounced at 48 h and 72 h, and tested with SUPM2/TS and JB-6 cell lines OTX-015 showed ability to increase cell death rate [3].In BLAB/c-nu/nu mice model with established Ty82 BRD-NUT midline carcinoma xenografts, oral administration of OTX-015 markedly inhibited tumor growth and reduced tumor volume [1].

          [1]. J. Kay Noel, Kazunori Iwata, Shinsuke Ooike, et al. Development of the BET bromodomain inhibitor OTX015 [J]. Mol Cancer Ther November 2013 12; C244.
          [2]. Fu LL, Tian M, Li X, et al. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery [J]. Oncotarget. 2015 Mar 20;6(8):5501-5516.
          [3]. Michela Boi, Maria Todaro, Valentina Vurchio, et al. OTX015, a bromodomain and extraterminal inhibitor, represents a novel agent for ALK positive anaplastic large cell lymphoma [J]. Mol Cancer Ther November 2013 12; A219.

      • Properties
        • Alternative Name
          OTX 015;OTX015
          CAS Number
          202590-98-5
          Molecular Formula
          C25H22ClN5O2S
          Molecular Weight
          491.99
          Purity
          98.17%
          Solubility
          ≥24.6 mg/mL in DMSO; insoluble in H2O; ≥106 mg/mL in EtOH with gentle warming
          Storage
          Store at -20°C

          * For Research Use Only

      • Reference
        • 1. Te Zhang, Xuming Song, et al. "Aberrant super-enhancer landscape reveals core transcriptional regulatory circuitry in lung adenocarcinoma." Oncogenesis. 2020 Oct 17;9(10):92. PMID:33070167
          2. Zhao M, De Crignis E, et al. "T cell toxicity of HIV latency reversing agents." Pharmacol Res. 2018 Oct 23. pii: S1043-6618(18)30970-8. PMID:30366100
          3. Qian G, Yao W, et al. "Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy." Cancer Lett. 2018 Oct 28;435:44-54. PMID:30059709
          4. Abner E, Stoszko M, et al. "A new quinoline BRD4 inhibitor targets a distinct latent HIV-1 reservoir for re-activation from other 'shock' drugs." J Virol. 2018 Jan 17. pii: JVI.02056-17. PMID:29343578

    Note: If you don't receive our verification email, do the following:

  • Copyright © Amerigo Scientific. All rights reserved.